A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 11 Oct 2017 Planned number of patients changed from 15 to 20.
- 21 Feb 2017 Phase has been changed from Phase 0 to phase 1
- 21 Feb 2017 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.